Available Treatments

  1. HOME
  2. Available Treatments
  3. Pediatric(Congenital) Heart Disease Treatments

Pediatric(Congenital) Heart Disease Treatments

Congenital Heart Disease

We provide a range of treatments for patients with all kinds of congenital conditions. From simple congenital heart diseases (CHDs) such as atrial and ventricular septal defects, to complex diseases such as Tetralogy of Fallot, complete large vessel dislocation, or diseases requiring single-ventricle Fontan surgery. In addition, for expectant mothers whose child is suspected of CHD upon ultrasonic examination, we can organize treatment in collaboration with obstetrics and neonatal departments to respond in various ways immediately after birth.
Also, since 1956, when our department performed the first open heart surgery with a heart-lung machine, we have treated over 1,000 cases of CHD in patients who are now adults. Based on that experience, we now deal with various adult congenital heart diseases, so please feel free to consult us.

Pediatric (Congenital) Heart Disease Treatment

Pediatric Heart Failure

This department is one of only three pediatric heart transplant facilities in Japan, and treatment for children with severe heart failure is conducted jointly with the Department of Cardiovascular Pediatrics.

Depending on the severity of heart insufficiency, we offer a wide range of treatments from medication to ventricular assist devices. In addition, together with other pediatric cardiovascular treatment facilities, we form a network to correspond to patients nationwide, so please don't hesitate to consult us at any time.

Pediatric Heart Failure Treatment:Assisted Artificial Heart

Regenerative Medicine

Regenerative Therapy with Autologous Skeletal Myoblast Sheets

As part of a new initiative, we are also introducing skeletal myoblast treatments for children.

New High-Durability Artificial Valve Treatment

It has been discovered that when using a donor pulmonary artery, and a valve produced by a process known as decellularization, the decellularized valve is replaced with the bodies own cells, after surgery. This is expected to lead to more durable artificial valves in the future.